Salvatore Salamone

Salvatore Salamone is a scientist and researcher within diagnostic medicine and therapeutic drug monitoring. He is responsible for the development of many of the major reagents used within psychiatric drug level monitoring.[1][2] Salamone is the founder of Saladax Biomedical, Inc.[3] His contributions to diagnostic medicine have been recognized through several local awards, including the Ben Franklin Innovation Award[4] and the New Jersey Inventors Hall of Fame in 2016.[5] Salamone has 70 FDA-approved products and more than 200 instrument applications. He is the editor of a textbook on benzodiazapines[6] and is also the holder of 41 issued US patents.[7]

Education

Salamone earned two bachelor's degrees from Villanova University, a master's and a PhD degree from Rutgers University and was a Science Engineering Research Council (SERC) Post-Doctoral Fellow at the University of Oxford, UK.[3]

References
  1. Acton, Q. Ashton (2013). Schizophrenia: New Insights for the Healthcare Professional. ScholarlyEditions. p. 434. ISBN 9781481655712.
  2. , "Clozapine immunoassay", issued 2011-07-19
  3. "Bloomberg - Salvatore J Salamone". www.bloomberg.com. Retrieved 2020-01-15.
  4. "Ben Franklin Announces Innovation Award Winners". BFTP | NEP. 2009-04-17. Retrieved 2020-01-15.
  5. "2016 Awardees". NJ Inventors Hall of Fame 2018. Retrieved 2020-01-15.
  6. Salamone, Salvatore J (2001). Benzodiazepines and GHB: detection and pharmacology. Totowa, N.J.: Humana Press. ISBN 978-0-89603-981-0. OCLC 46463342.
  7. "Salvatore J. Salamone Inventions, Patents and Patent Applications - Justia Patents Search". patents.justia.com. Retrieved 2020-01-15.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.